Clinical Trials in Philadelphia

Showing 17721-17740 of 20,904 trials

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

NCT01756053

This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089 (an experimental medication not approved by the FDA) when administered as 40mg oral once daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive deficits, smoking withdrawal, smoking urges, smoking reward, and a brief, monitored quit attempt (\~4 days). The key cognitive domains include: working memory, sustained attention, and response inhibition.

Nicotine Addiction

University of Pennsylvania17 participantsStarted Mar 2013

Philadelphia, Pennsylvania, United States

COMPLETEDNA< 1 mile

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

NCT01299259

The investigators hypothesize that text message reminders to girls diagnosed with pelvic inflammatory disease (PID) in the emergency department (ED) will improve follow-up to their primary care provider (PCP) after being discharged from the ED.

Pelvic Inflammatory Disease

Children's Hospital of Philadelphia95 participantsStarted Feb 2011

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694

The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.

Pulmonary Disease, Chronic Obstructive

Boehringer Ingelheim470 participantsStarted Nov 2009

Jasper, Alabama, United States • Mobile, Alabama, United States • Mesa, Arizona, United States +52 more locations

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Find Trials by Condition in Philadelphia

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

Open-Label Phase III Long-Term Safety Trial of Liprotamase

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

Phase III ALTU-135 CP Safety Trial

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.

Minocycline in Acute Spinal Cord Injury (MASC)

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)